← Oncology Approval Tracker

FDA DECISION ·

Verzenio + endocrine therapy

abemaciclib with tamoxifen or an aromatase inhibitor · Eli Lilly

FDA approvalNew or expanded indicationBreast cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Adults with node-positive HR-positive, HER2-negative early breast cancer at high risk of recurrence and Ki-67 of at least 20% by an FDA-approved test, in combination with endocrine therapy. FDA later removed the Ki-67 requirement.

LAMPGEN ANALYSIS

Why it matters

The 2021 adjuvant action used a Ki-67 threshold that changed in 2023.

What research teams should watch

Preserve the pathology, nodal risk features, assay result and label version when analyzing historical eligibility.

PRIMARY RECORDS

Sources